SuperGen has announced the issuance of U.S. Patent No. 7,037,900 B2 entitled, "Composition and Method for Treating Graft-versus-Host Disease." The patent contains 39 claims relating to the com
Cutera today announced that it has settled all patent infringement lawsuits with Palomar Medical Technologies, Inc. As part of this transaction, Cutera and Palomar have agreed to refrain from a
Nventa Biopharmaceuticals Corporation announced that the European Patent Office has granted Patent Number EP 941,315 to Nventa. The patent covers compositions of fusion proteins comprised of
Could a substance found in green leaves be used as a means of combating obesity, by being added to various functional foods to keep the consumer feeling full longer? This is the hope of a research team at
Sirna Therapeutics has announced that its objections to the Kreutzer-Limmer patent in Europe were accepted by the European Patent Office, resulting in both a significant narrowing of the patent claims an
Gen-Probe has announced that Bayer HealthCare LLC has agreed to end a series of disputes involving multiple patent litigations and contract arbitrations. Under the binding terms of the agreem
Ryogen and R&D Systems have announced that they have entered into a nonexclusive license agreement whereby RDSI has licensed from Ryogen the patent directed to the clinically important Aminopeptida
CAS Medical Systems has announced that it has been awarded two United States Patents for technology used in its Fore-Sight Cerebral Oximeter, which is scheduled for commercial release in late 2006.
Advanced Medical Optics has announced that it has reached a settlement with Alcon, Inc., Alcon Manufacturing, Ltd. and Alcon Laboratories, Inc., resolving all pending patent infringement lawsuits betwe
Synergetics USA has announced its response to the recent Markman ruling delivered in the pending patent infringement lawsuit brought by Iridex Corporation against Synergetics relating to Iridex'
GTI-2040 is currently the subject of a Clinical Trials Agreement with the United States National Cancer Institute (NCI) under which GTI-2040 is being tested in combination with chemotherapy in five different clinical trials. These include studies of GTI 2040 in breast, lung, colon, acute myeloid leukemia and a variety of solid tumors.
Promising phase II interim clinical data arising from GTI-2040 in combination therapy for the treatment of renal cell carcinoma has provided evidence of disease stabilizations, tumor reductions and a favourable safety profile at the recommended phase II dose. Patients in the clinical study had previously failed or were ineligible for standard therapies, and were representative of a population with very poor prognostic outcome.
GTI-2501 is a novel antisense drug which has shown a favorable safety profile in preclinical studies, and in a phase I clinical trial. The drug is in a phase II clinical trial in combination with docetaxel for the treatment of hormone refractory prostate cancer. Initial testing has demonstrated strong antitumor activity in preclinical studies in prostate cancer and a variety of other tumor types.
In addition to this Canadian patent allowance, GTI-2040 and GTI-2501 have been protected by patents issued by the United States, Singapore, Australian and New Zealand Patent Offices. Patent applications for these antisense drugs have also been filed in numerous other international jurisdictions.
"Lorus Therapeutics is focused on developing anticancer drugs which complement the efficacy of more toxic chemotherapies without adding significant additional toxicity," said Dr. Jim Wright, CEO of Lorus Therapeutics. "We were pleased with the safety profile previously seen with GTI-2040 alone, and its positive clinical results to date in combination treatment for kidney cancer."
Added Dr. Wright: "This Canadian patent allowance contributes to our strong global intellectual property portfolio, an important part of our strategy for the creation of value within Lorus."
GTI-2040 is an antisense oligonucleotide complementary to the R2 component of ribonucleotide reductase, an activity that is essential for DNA synthesis. R2 is frequently over-expressed in cancer cells, and has been shown to cooperate with a variety of oncogenes to increase the tumorigenic and malignant potential of cancer cells. GTI-2501 is designed to exert its activity by specific downregulation of the R1 component of ribonucleotide reductase, a component essential for DNA replication and tumor cell proliferation.
http://www.lorusthera.com/